MariMed 10-Q: Record $44.2M Q3 Revenue, But Net Loss Widens to $3.5M
MRMD sits 67% above its 52-week low of $0.045.
Summary
MariMed's Q3 10-Q confirms record $44.2M revenue but a wider $3.5M net loss, with $34.2M of income taxes payable (including ~$7M of disputed IRS liens) and $10.4M of cash against $78.2M of debt.
Key Events · Earnings and Guidance · MRMD
-
Record Q3 Revenue, Wider Net Loss
Revenue rose 8.5% to $44.2M from $40.8M, but net loss widened to $3.5M from $2.9M and gross margin fell to 38.8% from 40.1% on competitive pricing pressure.
-
Tax Liabilities and Disputed IRS Liens
Income taxes payable reached $34.2M versus $27.0M at December 31, 2025, including an approximate $6M 2023 lien and an approximate $1M FSC lien for 2023-2024, both under dispute via Collection Due Process hearings.
-
Series B Restructuring Extinguished $14.2M Obligation
The February 24, 2026 agreement cancelled the old Series B stock and its $14.2M obligation, issuing $8.0M of new notes (8.0% due 2028, 10.0% due 2031) plus 26.9M New Series B preferred shares with a $6.725M liquidation preference, booking a $0.7M gain.
-
Liquidity and Debt Load
Cash, cash equivalents and restricted cash were $10.4M against $78.2M of mortgages and notes payable; nine-month operating cash flow was $6.7M versus $4.3M a year earlier.
Analysis · MRMD · Life Sciences
The headline numbers were already out on November 11, but the full 10-Q reveals the quality of the quarter: revenue grew 8.5% to $44.2M while gross margin slipped to 38.8% from 40.1% on pricing pressure, and the net loss widened to $3.5M from $2.9M. The balance sheet carries the real weight — income taxes payable climbed to $34.2M from $27.0M at year-end, including roughly $7M of disputed IRS liens the company is fighting through Collection Due Process hearings. Liquidity is adequate for now: $10.4M of cash and restricted cash against $78.2M of mortgages and notes, with management stating current cash covers at least the next twelve months. The February Series B restructuring removed a $14.2M obligation in exchange for $8.0M of new notes and 26.9M New Series B preferred shares, and the April DOJ Schedule III order cut tax expense by $1.2M in the nine months.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MRMD was trading at $0.08 on OTC in the Life Sciences sector, with a market capitalization of approximately $30.3M. The 52-week trading range was $0.05 to $0.16. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.